NASDAQ · Biotechnology

TVTX (TVTX) Stock

$55.56 -0.63% NASDAQ: TVTX Healthcare

Valuation

MetricValue
Price$55.56
Market Cap$5.17B
P/E Ratio8.56
P/B Ratio33.92
P/S Ratio7.43
EPS (TTM)$-0.50
52-Week High$59.89
52-Week Low$13.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.38%
ROA-6.46%
ROCE-54.71%
Gross Margin55.95%
Operating Margin-29.02%
Net Margin-4.00%
Debt/Equity3.32
Current Ratio3.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$132.0M$109.0M$145.0M$233.0M$491.0M
Operating Profit$-199.0M$-320.0M$-388.0M$-324.0M$-63.0M
Net Profit$-180.0M$-278.0M$-111.0M$-322.0M$-26.0M
EPS$-3.01$-4.37$-1.50$-4.08$-0.56
Op Margin-151.3%-292.2%-267.2%-138.9%-12.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$777.0M$673.0M$789.0M$594.0M$605.0M
Total Liabilities$475.0M$630.0M$588.0M$535.0M$490.0M
Cash$166.0M$62.0M$58.0M$59.0M$93.0M
Borrowings$262.0M$407.0M$405.0M$402.0M$329.0M

Latest News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 10, 2026 Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 MT Newswires · Jul 10, 2026 Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says MT Newswires · Jun 22, 2026 Wedbush Adjusts Price Target on Travere Therapeutics to $61 From $55, Maintains Outperform Rating MT Newswires · Jun 22, 2026 Travere Therapeutics Chief Research Officer William Rote to Retire MT Newswires · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-186.0M$-280.0M$-237.0M$38.0M
Investing Cash Flow$-162.0M$-61.0M$14.0M$-2.0M$28.0M
Financing Cash Flow$7.0M$-7.0M$28.0M$5.0M$-2.0M
Net Cash Flow$81.0M$-104.0M$-4.0M$0$35.0M
Free Cash Flow$-39.0M$-215.0M$-322.0M$-339.0M$38.0M

Valuation & Return Ratios

MetricValue
PEG Ratio9.30
EV / EBITDA251.54
FCF Yield0.44%
Quick Ratio3.08
Interest Coverage-5.73
Return 1Y257.65%
Return 3Y251.21%
Return 5Y335.90%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $134.19 +0.06% -16.89 $8.30B 0.00%
CELC $92.49 +5.44% -91.68 $4.51B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%

About TVTX

TVTX stock trades at $55.56 with a market capitalization of $5.17B. The stock is valued at a price-to-earnings (P/E) ratio of 8.56, price-to-book of 33.92, price-to-sales of 7.43. Over the past 52 weeks the stock has ranged between $13.88 and $59.89, and currently trades 7.2% below its 52-week high.

On profitability, TVTX generates a return on equity (ROE) of -69.38%, return on capital employed of -54.71%, an operating margin of -29.02%, a net profit margin of -4.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides